未登录

N

Nathan Collins

sri international

H指数:15

被引数:985

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction to: Constraining eruption timing and duration at Taranaki volcano, New Zealand, using Late Holocene stalagmites

更正：利用新西兰晚全新世石笋约束塔拉纳基火山的喷发时间和持续时间

Bulletin of Volcanology

IF3.2

2026-09-140

OA

Constraining eruption timing and duration at Taranaki volcano, New Zealand, using Late Holocene stalagmites

通过晚全新世石笋约束新西兰塔拉纳基火山的喷发时间和持续时间

Bulletin of Volcanology

IF3.2

2026-07-270

OA

SynRoute: A Retrosynthetic Planning Software

JOURNAL OF CHEMICAL INFORMATION AND MODELING

IF5.3

2023-08-284

OAAI

A Petrologic Insight into Transitioning Eruption Styles from the Devil's Rock Region, Ambae, Vanuatu

JOURNAL OF PETROLOGY

IF3.5

2022-06-130

OA

Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers

ACS CENTRAL SCIENCE

IF10.4

2022-01-114

OAAI

Fully Automated Chemical Synthesis: Toward the Universal Synthesizer

全自动化学合成: 走向通用合成器

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2020-06-2356

PREAI

Mirror Molecules in Space

SCIENTIFIC AMERICAN

IF3.1

2016-08-160

PREAI

Using Fiber Array Scanning Technology (FAST) Platform for sensitive detection and analysis of circulating tumor cells with a hybrid epithelial/mesenchymal phenotype from non-small cell lung cancer.

MOLECULAR CANCER THERAPEUTICS

IF5.5

2013-11-010

PRE

Antitumor activity of SR16388 on multiple myeloma targets factors needed for adaptation to bone marrow microenvironment

CANCER RESEARCH

IF16.6

2011-04-010

PRE

SR13668, a selective 12-lipoxygenase inhibitor, suppresses tumor growth by modulating the Akt signaling pathway

CANCER RESEARCH

IF16.6

2011-04-010

PRE

SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo

IF9.2

2010-11-2110

PRE

A novel steroidal inhibitor of estrogen-related receptor α (ERRα)

雌激素相关受体 α (err α) 的新型甾体抑制剂

BIOCHEMICAL PHARMACOLOGY

IF5.6

2010-09-0140

OAAI

Nonprofit model for drug discovery and development

DRUG DEVELOPMENT RESEARCH

IF4.2

2007-10-263

PREAI

X-RAY STRUCTURE OF [D-PEN(2),D-PEN(5)]ENKEPHALIN, A HIGHLY POTENT, DELTA-OPIOID RECEPTOR-SELECTIVE COMPOUND - COMPARISONS WITH PROPOSED SOLUTION CONFORMATIONS

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

IF15.6

2002-05-0166

PREAI

DESIGN, SYNTHESIS, AND BIOLOGICAL PROPERTIES OF HIGHLY POTENT CYCLIC DYNORPHIN-A ANALOGS - ANALOGS CYCLIZED BETWEEN POSITION-5 AND POSITION-11

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2002-05-0131

PREAI

Solution conformations of potent bicyclic antagonists of oxytocin by nuclear magnetic resonance spectroscopy and molecular dynamics simulations

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

IF15.6

1997-06-2521

PREAI

Novel amphiphilic phthalocyanines: Formation of Langmuir-Blodgett and cast thin films

IF3.9

1996-10-0293

PREAI

Conformational determinants of agonist versus antagonist properties of [D-Pen(2),D-Pen(5)]enkephalin (DPDPE) analogs at opioid receptors. Comparison of x-ray crystallographic structure, solution H-1 NMR data, and molecular dynamic simulations of [L-Ala(3)]DPDPE and [D-Ala(3)]DPDPE

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

IF15.6

1996-03-0638

PREAI

Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphin A(1-11)-NH21

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

1996-03-0131

PREAI